Andere Sprachen Bausch + Lomb Corporation Toronto S.E.

Aktien

A3DLMS

CA0717051076

BLCO

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:20:16 24.05.2024			% 5 Tage	% 1. Jan.
20.61 ^CAD	+1.63%		+3.46%	-9.09%

06.05.	Bausch + Lomb-Aktien steigen nach Hochstufung durch Morgan Stanley	MT
06.05.	BAUSCH + LOMB CORPORATION : Morgan Stanley gibt eine Kauf-Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Bausch Health Companies - Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	20.05.
Bausch Health Announces 2024 Annual Meeting of Shareholder Results	16.05.
Bausch + Lomb : 2023 Report	16.05.
Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	06.05.
Bausch Health Announces First Quarter 2024 Results	03.05.
RBC Capital Reviews Bausch + Lomb's Q1 Results	02.05.
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	01.05.
Bausch + Lomb Q1 Loss Widens, Revenue Increases	01.05.
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	01.05.
Bausch + Lomb: Q1 Earnings Snapshot	01.05.
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	01.05.
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	01.05.
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	01.05.
Bausch + Lomb Announces First-Quarter 2024 Results	01.05.
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	01.05.
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting	29.04.
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	25.04.
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	25.04.
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25.04.
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Bausch + Lomb Corporation Toronto S.E.

Aktien

A3DLMS

CA0717051076

BLCO

Andere Sprachen

Filter